Sign up to save your podcasts
Or
Share What’s on the Horizon for Dementia Care? (And the FDA’s Decision on aducanumab) with Dr. Jason Karlawish
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
What’s on the Horizon for Dementia Care? (And the FDA’s Decision on aducanumab) with Dr. Jason Karlawish
In his new book The Problem of Alzheimer’s, Dr. Jason Karlawish from the Penn Memory Center traces the history of a condition that impacts nearly 6 million Americans at a cost of more than $225 billion annually. These numbers may triple over the next decade. In today’s episode, Dr. Karlawish discusses potential breakthroughs in the years ahead – both pharmacologic and social – that can help us weather this storm. We also review the FDA’s controversial approval last week of aducanumab, the first new drug for Alzheimer’s in nearly two decades.
**Be sure to subscribe to The Healthy Skeptic MD on your favorite podcast app and on Youtube!
Link for our channel on podcast apps and Youtube: wavve.link/healthyskepticmd
View all episodes
By Dr. Michael Hochman, MD
5
3838 ratings
In his new book The Problem of Alzheimer’s, Dr. Jason Karlawish from the Penn Memory Center traces the history of a condition that impacts nearly 6 million Americans at a cost of more than $225 billion annually. These numbers may triple over the next decade. In today’s episode, Dr. Karlawish discusses potential breakthroughs in the years ahead – both pharmacologic and social – that can help us weather this storm. We also review the FDA’s controversial approval last week of aducanumab, the first new drug for Alzheimer’s in nearly two decades.
**Be sure to subscribe to The Healthy Skeptic MD on your favorite podcast app and on Youtube!
Link for our channel on podcast apps and Youtube: wavve.link/healthyskepticmd